Safety remains in focus for Cogent’s bezuclastinib
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
The complex web of PARP inhibitor development
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Black Diamond picks its lung cancer battle
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
Merck KGaA’s oncology catalyst approaches
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
Cell cycle niche seeks clinical validation
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
